证券代码：688553 证券简称：汇宇制药 公告编号：2024-034 四川汇宇制药股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 股东大会召开日期：2024年5月17日 本次股东大会涉及每一特别表决权股份享有的表决权数量应当与每一 普通股份的表决权数量相同的议案 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开地点：四川省成都市双流区歧黄二路 1533 号会议室 （五） 网络投票的系统、起止日期和投票时间。 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六 ...

四川汇宇制药股份有限公司 内部控制审计报告 + 目 录 | | | | 二、附件………………………………………………………… 第 | 3—6 | 页 | | --- | --- | --- | | （一）本所营业执照复印件…………………………………………第 | 3 | 页 | | （二）本所执业证书复印件…………………………………………第 | 4 | 页 | | （三）执业注册会计师资格证书复印件…………………………第 | 5-6 | 页 | 内部控制审计报告 天健审〔2024〕11-188 号 三、内部控制的固有局限性 第 1 页 共 6 页 我们认为，汇宇制药公司于 2023 年 12 月 31 日按照《企业内部控制基本规 范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 四川汇宇制药股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要 ...

中信建投证券股份有限公司关于 四川汇宇制药股份有限公司 暂时调整募投项目闲置场地用途的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为四川汇宇制药股份有限公司（以下简称"上市公司""汇宇制药"或"公司"） 首次公开发行股票并在科创板上市的持续督导保荐机构，根据《证券发行上市保 荐业务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等有关法律、法规的规定，对上市公司暂时调整募投项目闲置场地用途事项 进行了认真、审慎的核查，并发表核查意见如下： 一、募集资金基本情况 经上海证券交易所科创板上市委员会 2021 年 5 月 26 日审核同意，并经中国 证券监督管理委员会于 2021 年 8 月 3 日《关于同意四川汇宇制药股份有限公司 首次公开发行股票注册的批复》（证监许可〔2021〕2596 号）同意注册，汇宇制 药向社会公开发行人民币普通股（A 股）股票 63,600,000 股，发行价格 38.87 元/股，本次发行的募集资金总额为 247,213.20 万元，扣除相关发行费 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥242,604,188.27, representing a year-on-year increase of 2.05%[4] - The net profit attributable to shareholders was ¥46,435,905.16, reflecting a significant increase of 20.94% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 110.53% to ¥37,514,613.03[4] - The basic and diluted earnings per share both stood at ¥0.11, marking a 20.95% increase year-on-year[4] - Total operating revenue for Q1 2024 was ¥242,604,188.27, an increase of 2.4% compared to ¥237,720,069.60 in Q1 2023[15] - Net profit for Q1 2024 was ¥44,879,334.61, up 16.3% from ¥38,395,308.10 in Q1 2023[16] - Earnings per share for Q1 2024 increased to ¥0.11, compared to ¥0.09 in Q1 2023[17] - The total comprehensive income for Q1 2024 was ¥44,948,732.88, compared to ¥38,456,769.97 in Q1 2023, reflecting an increase of 16.4%[17] Assets and Liabilities - The company's total assets increased by 2.63% to ¥4,808,881,819.76 compared to the end of the previous year[5] - As of March 31, 2024, the total assets of the company amounted to RMB 4,808,881,819.76, an increase from RMB 4,685,645,273.96 as of December 31, 2023, reflecting a growth of approximately 2.65%[12] - The company's current assets totaled RMB 2,971,856,903.97, up from RMB 2,870,156,288.20, indicating an increase of about 3.8%[12] - The company's total liabilities were RMB 989,509,625.27, an increase from RMB 911,221,812.34, marking a rise of around 8.6%[13] - The short-term borrowings increased to RMB 562,314,511.12 from RMB 426,732,400.71, reflecting a significant increase of approximately 31.7%[13] - The company's non-current assets totaled RMB 1,837,024,915.79, slightly up from RMB 1,815,488,985.76, indicating a growth of approximately 1.2%[12] - The company's equity remained stable at RMB 3,819,372,194.49, unchanged from the previous reporting period[13] Cash Flow and Investments - The net cash flow from operating activities was reported at ¥13,438,049.99, with no applicable year-on-year comparison[4] - Cash inflow from operating activities rose to ¥305,376,969.17 in Q1 2024, compared to ¥237,486,856.73 in Q1 2023, marking a growth of 28.6%[19] - The net cash flow from operating activities for Q1 2024 was $13,438,049.99, a significant improvement compared to a net outflow of $55,773,582.18 in Q1 2023[20] - Total cash inflow from investment activities was $420,350,601.27, down from $1,468,048,166.06 in the previous year, indicating a decrease of approximately 71.4%[20] - The net cash flow from investment activities for Q1 2024 was $39,578,048.79, recovering from a net outflow of $13,408,276.21 in Q1 2023[20] - Cash inflow from financing activities totaled $268,781,611.11, compared to $114,500,000.00 in the same quarter last year, representing an increase of approximately 134%[20] - The net cash flow from financing activities was $131,884,679.85, up from $114,180,534.03 in Q1 2023, showing a growth of about 15.5%[20] - The ending balance of cash and cash equivalents as of Q1 2024 was $1,814,964,936.81, an increase from $1,250,847,149.19 at the end of Q1 2023, reflecting a growth of approximately 45%[21] - Total cash and cash equivalents increased by $184,900,778.63 in Q1 2024, compared to an increase of $44,998,675.64 in Q1 2023, indicating a substantial improvement in liquidity[20] Research and Development - Research and development expenses totaled ¥67,248,405.84, which is a decrease of 20.07% year-on-year[4] - The proportion of R&D expenses to operating revenue was 27.72%, down by 7.67 percentage points from the previous year[5] - Research and development expenses decreased to ¥65,507,169.10 in Q1 2024 from ¥84,139,195.36 in Q1 2023, a decline of 22.2%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,551[9] - The company's minority interest loss was ¥1,556,570.55 in Q1 2024, with no prior year comparison available[16] Employee Compensation and Tax - The company paid $78,046,471.47 in cash to employees in Q1 2024, down from $91,160,295.69 in the same period last year, a decrease of about 14.4%[20] - Tax payments increased to $31,925,712.64 in Q1 2024 from $12,312,412.29 in Q1 2023, representing a significant rise of approximately 159%[20]

四川汇宇制药股份有限公司 证券代码：688553 证券简称：汇宇制药 公告编号：2024-037 2023年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第2号—上市公司募集资金管理和使用的监管要求》 《上海证券交易所科创板上市公司自律监管指引第1号—规范运作》及相关业务规 则的规定，四川汇宇制药股份有限公司(以下简称"公司")编制了截至2023年12 月31日的《公司2023 年度募集资金存放与使用情况的专项报告》，现将相关情况 报告如下： 一、 募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意四川汇字制药股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕2596号）核准，并经上海证券交易所 同意，公司由主承销商中信建投证券股份有限公司采用余额包销方式，向社会公 众公开发行人民币普通股（A股）股票63,600,000股，发行价为每股人民币38.87 元，共计募集资金2,472,132,000.00元，坐 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2024-038 四川汇宇制药股份有限公司 关于暂时调整募投项目闲置场地用途的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、募集资金基本情况 经上海证券交易所科创板上市委员会 2021 年 5 月 26 日审核同意，并经中国 证券监督管理委员会于 2021 年 8 月 3 日《关于同意四川汇宇制药股份有限公司 首次公开发行股票注册的批复》（证监许可〔2021〕2596 号）同意注册，汇宇制 药向社会公开发行人民币普通股（A 股）股票 63,600,000 股，发行价格 38.87 元 /股，本次发行的募集资金总额为 247,213.20 万元，扣除相关发行费用人民币 11,145.72 万元，募集资金净额为人民币 236,067.48 万元。天健会计师事务所（特 四川汇宇制药股份有限公司（以下简称"公司"或"汇宇制药"）拟暂时调 整"汇宇创新药物研究院建设项目"部分闲置场地用途，将进行对外出租， 提高公司募投项目场地利用率。 公司于 2024 ...

中信建投证券股份有限公司 关于四川汇宇制药股份有限公司 2023年度募集资金存放与实际使用情况的专项核查意见 中信建投证券股份有限公司（以下简称"中信建投证券""保荐机构"）作 为四川汇宇制药股份有限公司(以下简称"汇宇制药"或"公司")首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法（2023 年修订）》《上市公司监管指引第2号——上市公司募集资金管理和使用的监管 要求（2022年修订）》《上海证券交易所科创板上市公司自律监管指引第1号— —规范运作》等有关规定，就汇宇制药截至2023年12月31日募集资金存放与实际 使用情况进行了审慎核查，并出具核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意四川汇字制药股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕2596号）核准，并经上海证券交易所 同意，公司由主承销商中信建投证券股份有限公司采用余额包销方式，向社会公 众公开发行人民币普通股（A股）股票63,600,000股，发行价为每股人民币38.87 元，共计募集资金2,472,132,000.00元，坐 ...

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 139,785,741.88 for the year 2023, with a cumulative distributable profit of RMB 836,323,714.02 as of December 31, 2023[6]. - The proposed cash dividend is RMB 2.13 per 10 shares (including tax), totaling RMB 89,771,762.14, which accounts for 64.22% of the net profit attributable to shareholders for 2023[6]. - The company's operating revenue for 2023 was ¥927,075,092.41, a decrease of 37.92% compared to ¥1,493,267,942.75 in 2022[36]. - The net profit attributable to shareholders for 2023 was ¥139,785,741.88, down 43.86% from ¥248,990,617.28 in 2022[36]. - The basic earnings per share for 2023 was ¥0.33, a decline of 44.07% from ¥0.59 in 2022[38]. - The net cash flow from operating activities for 2023 was ¥66,932,697.85, a decrease of 65.51% from ¥194,060,349.44 in 2022[36]. - The net profit after deducting non-recurring gains and losses for 2023 was ¥66,010,570.30, down 66.69% from ¥198,163,722.79 in 2022[36]. - The company's main business gross margin for 2023 is 85.94%, a decrease of 2.26 percentage points year-on-year[115]. - The total revenue for the year reached approximately ¥6.07 billion, with a significant portion attributed to high-quality generic drugs and innovative therapies[104]. Governance and Shareholder Rights - The company’s board of directors and supervisory board have confirmed the accuracy and completeness of the annual report, ensuring compliance with legal responsibilities[4]. - The company has implemented measures to protect minority shareholders' interests against potential abuses of special voting rights[15]. - The company’s governance structure includes provisions for minority shareholders to convene extraordinary meetings and propose agenda items[15]. - The company has established a special voting rights mechanism that allows the actual controller to have decisive control over ordinary resolutions at shareholder meetings[14]. - The company emphasizes the importance of independent directors in corporate governance, ensuring their voting rights are equal to ordinary shares during appointments and dismissals[18]. - The company has three independent directors who supervise corporate governance, enhancing the oversight of major related transactions and external guarantees[18]. - The company will strictly adhere to the Shanghai Stock Exchange's regulations regarding special voting rights and disclose relevant arrangements in periodic reports[20]. Research and Development - Research and development expenses accounted for 38.48% of operating revenue in 2023, an increase of 14.63 percentage points from 23.85% in 2022[38]. - The company invested RMB 356.72 million in R&D during 2023, with over RMB 105 million allocated to innovative drug development, reflecting a 17.46% increase compared to the previous year[49]. - The company has 13 innovative drug projects under development, including the dual-target small molecule project HY-0002a, which received IND approval in October 2023[48]. - The company submitted 39 invention patent applications and obtained 16 new patents during the reporting period, bringing the total to 158 applications and 33 granted patents[89]. - The company has established 4 research institutes to focus on the development of quality generic drugs and innovative drugs in the oncology field[62]. - The company has developed a dual-target small molecule drug design platform, enhancing its capabilities in innovative drug development[86]. - The company is focusing on innovative drug development in oncology, aiming to address clinical needs and reduce adverse reactions through targeted therapies[108]. Market and Product Development - The company has a strong pipeline of products, with a focus on oncology, including drugs for breast cancer, lung cancer, and hematological malignancies, reflecting a commitment to expanding its therapeutic offerings[175]. - The company is actively pursuing the development of complex injectables and has several products in the registration review process, including ET142 for small cell lung cancer[168]. - The company is pursuing market expansion strategies, evidenced by the approval of multiple products in international markets, enhancing its global footprint[176]. - The company has received 9 new drug approvals in the domestic market and 59 approvals in overseas markets, with a total of over 320 drug approvals held globally[49]. - The company is committed to maintaining high standards in drug development and regulatory compliance, as demonstrated by the successful approval of multiple products across different categories[174]. Risks and Challenges - The company faces risks related to price declines in products due to national procurement policies, which could significantly impact revenue stability in the coming years[4]. - The company faces risks related to innovation and regulatory changes, which could impact the timeline and success of new drug approvals[110]. - The company is at risk of declining drug prices due to national price negotiations and competitive pressures[119]. - The company faces risks related to the inability to win bids in centralized procurement, which could adversely affect sales and profitability[112]. - The company has a risk of losing core technical personnel, which is critical for maintaining its competitive advantage in R&D and production[111]. International Operations - The company exports products to over 50 countries, exposing it to foreign exchange risks that could impact profitability[116]. - The company’s international sales revenue reached nearly RMB 86 million, representing a growth of over 55% compared to the same period last year[50]. - The company has submitted 71 drug applications for regulatory approval in foreign markets during the reporting period[171]. - The company is collaborating with authorized partners for several drug applications in regions including Australia, Canada, and various European countries[172]. Future Outlook - The company aims to provide effective, high-quality, and reasonably priced drugs for global patients, with a mission to make cancer a controllable chronic disease[200]. - The company is transitioning from a model of "generics supporting innovation" to a focus on "innovation as the primary driver" in the medium to long term[200]. - The company aims to become a leading enterprise in the oncology field, evidenced by its core data in terms of the number of reviewed products, market share, and sales revenue[200].

证券代码：688553 证券简称：汇宇制药 公告编号：2024-039 的总股本扣减公司回购专用证券账户中股份为基数，向全体股东每 10 股派发现 金红利人民币 2.13 元（含税），不进行资本公积转增股本，不送红股。 四川汇宇制药股份有限公司 2023 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：A 股每股派发现金红利 0.213 元（含税），公司不送红 股、不以资本公积转增股本。 本次利润分配以实施权益分派股权登记日登记的四川汇宇制药股份有 限公司（以下简称公司）总股本扣减公司回购专用证券账户中的股份为基数为基 数，具体日期将在权益分派实施公告中明确。 如在本报告披露之日起至实施权益分派股权登记日期间，因可转债转 股、回购股份、股权激励授予股份回购注销、重大资产重组股份回购注销等致使 公司总股本发生变动的，公司拟维持分配总额不变，相应调整每股分配比例。如 后续总股本发生变化，将另行公告具体调整情况。 一、利润分配方案内容 经天健会计师事务所（特殊普通合伙）审计，公司 ...

中信建投证券股份有限公司关于 四川汇宇制药股份有限公司调整 2024 年度 日常关联交易预计额度的核查意见 单位：万元 中信建投证券股份有限公司（以下简称"中信建投证券""保荐人"）作为四 川汇宇制药股份有限公司（以下简称"汇宇制药""公司"）首次公开发行股票并 在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交 易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》等有关规定，对汇宇制药调整 2024 年度日常关联交易预计额度 事项进行了核查，核查情况及核查意见如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于 2024 年 1 月 16 日召开了第二届董事会第六次会议和第二届监事会第 六次会议，审议通过《关于预计公司 2024 年度日常性关联交易的议案》，关联董 事丁兆回避表决，出席会议的非关联董事一致同意该议案，审议程序符合相关法 律法规的规定。公司 2024 年日常性关联交易预计金额合计不超过人民币 2,260 万元。公司全体独立董事就上述议案发表了事前认可意见及明确同意的独立意见。 内容详见公司于 2024 年 1 月 1 ...